Download PDF
Exp Clin Endocrinol Diabetes 2003; 111(8): 455-470
DOI: 10.1055/s-2003-44704
Review

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

The Effect of Levothyroxine Therapy on Bone Mineral Density: A Systematic Review of the Literature

R. Schneider 1 , C. Reiners 1
  • 1Clinic for Nuclear Medicine, University of Würzburg, Würzburg, Germany
Further Information

Publication History

Received: January 29, 2003 First decision: April 14, 2003

Accepted: June 4, 2003

Publication Date:
09 January 2004 (online)

Also available at
    Permissions and Reprints

Abstract

Background

Currently debate still exists about the effects of thyroid hormone therapy on skeletal integrity, that is the safety of levothyroxine use with respect to bone mineral density.

Objective

A systematic review of the effects of TSH-suppressive and replacement levothyroxine therapy on bone mineral density evaluated main causes of conflicting results and its implications for clinical practice, and suggested directions of future research.

Data Source and Study Selection

A MEDLINE search identified English-language studies assessing bone mineral density under levothyroxine therapy published from 1990 to 2001.

Data Extraction

The studies were grouped by design and type of intervention. Outcomes were qualitatively analysed. Subgroup analysis assessed heterogeneity between studies.

Data Synthesis

Of 63 identified studies, 31 studies reported no effects of levothyroxine on bone mineral density, 23 studies showed partial beneficial or adverse, and 9 studies overall adverse effects. A significant dose-response was not found. There was a tendency towards peripheral cortical bone loss, suggesting a site-specific effect. In adolescents, men, and premenopausal women evidence for levothyroxine influence was weaker than in postmenopausal women. However, also findings in postmenopausal women remained unclear. The extent and etiology of underlying thyroid diseases also contributed to inconsistent results. Further, controversial results were due to substantial heterogeneity of studies. Above all, studies were limited by moderate quality, small size, and inadequate control for confounders.

Conclusions

Based on current studies there is insufficient evidence about effectiveness of levothyroxine on bone mineral density. All conclusions, however, must take into account the important methodical drawbacks. Present data may only be proved by longitudinal, high quality studies in homogeneous patients with sufficient sample size, clinical implication of future research remains questionable, though.

Key words

Levothyroxine therapy - bone mineral density

References

  • 1 Abugassa S, Nordenström J, Eriksson S, Sjöden G. Bone mineral density in patients with chronic hypoparathyroidism.  J Clin Endocrinol Metab. 1993;  76 1617-1621
    CrossrefPubMedSearch in Google Scholar
  • 2 Adlin E V, Maurer A H, Marks A D, Channick B J. Bone mineral density in postmenopausal women treated with L-thyroxine.  Am J Med. 1991;  90 360-366
    PubMedSearch in Google Scholar
  • 3 Affinito P, Sorrentino C, Farace M J, di Carlo C, Moccia G, Canciello P, Palomba S, Nappi C. Effects of thyroxine therapy on bone metabolism in postmenopausal women with hypothyroidism.  Acta Obstet Gynecol Scand. 1996;  75 843-848
    PubMedSearch in Google Scholar
  • 4 Allain T J, McGregor A M. Thyroid hormones and bone.  J Clin Endo. 1993;  139 9-18
    PubMedSearch in Google Scholar
  • 5 Arafah B M. Increased need for thyroxine in women with hypothyroidism during estrogen therapy:.  N Engl J Med. 2001;  344 1743-1749
    CrossrefPubMedSearch in Google Scholar
  • 6 Bauer D C, Nevitt M C, Ettinger B, Stone K. Low thyrotropin levels are not associated with bone loss in older women: A prospective study.  J Clin Endocrinol Meta. 1997;  82 2931-2936
    PubMedSearch in Google Scholar
  • 7 Campos-Pastor M M, Munoz-Torres M, Escobar-Jimenez F, de Almodovar M R, Gimeno E J. Bone mass in females with different thyroid disorders: influence of postmenopausal status.  Bone and Mineral. 1993;  21 1-8
    PubMedSearch in Google Scholar
  • 8 Collins R, MacMahon S. Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials.  Lancet. 2001;  357 373-380
    CrossrefPubMedSearch in Google Scholar
  • 9 Cummings S R, Bates D, Black D M. Clinical use of bone densitometry.  JAMA. 2002;  288 1889-1897
    CrossrefPubMedSearch in Google Scholar
  • 10 Demeester-Mirkine N, Bergmann P, Body J-J, Corvilain J. Calcitonin and bone mass status in congenital hypothyroidism.  Calcif Tissue Int. 1990;  46 222-226
    PubMedSearch in Google Scholar
  • 11 De Rosa G, Testa A, Maussier L, Calla C, Astazi P, Albanese C. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.  Horm Metab Res. 1995;  27 503-507
    PubMedSearch in Google Scholar
  • 12 De Rosa G, Testa A, Giacomini D, Carrozza C, Astazi P, Caradonna P. Prospective study of bone loss in pre- and postmenopausal women on L-thyroxine therapy for non-toxic goitre.  Clin Endocrinol (Oxf). 1997;  47 529-535
    CrossrefPubMedSearch in Google Scholar
  • 13 Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine signifcantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma.  J Clin Endocrin Metab. 1991;  72 1184-1188
    PubMedSearch in Google Scholar
  • 14 Duncan W E, Chang A, Solomon B, Wartofsky L. Influence of clinical characteristics and parameters associated with thyroid hormone therapy on the bone mineral density of women treated with thyroid hormone.  Thyroid. 1994;  4 183-190
    PubMedSearch in Google Scholar
  • 15 Faber J, Galloe A M. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis.  Eur J Endocrinol. 1994;  130 350-356
    PubMedSearch in Google Scholar
  • 16 Florkowski C M, Brownlie B E, Elliot J R, Ayling E M, Turner J G. Bone mineral density in patients receiving suppressive doses of thyroxine for thyroid carcinoma.  N Z Med J. 1993;  106 443-444
    PubMedSearch in Google Scholar
  • 17 Fowler P B, McIvor J, Sykes L, Macrae K D. The effect of long-term thyroxine on bone mineral density and serum cholesterol.  J R Coll Physicians Lond. 1996;  30 527-532
    PubMedSearch in Google Scholar
  • 18 Franklyn J A, Betteridge J, Daykin J, Holder R, Oates G D, Parle J V, Lilley J, Heath D A, Sheppard M C. Long-term thyroxine treatment and bone mineral density.  Lancet. 1992;  340 9-13
    CrossrefPubMedSearch in Google Scholar
  • 19 Franklyn J A, Betteridge J, Holder R, Daykin J, Lilley J, Sheppard M. Bone mineral density in thyroxine treated females with or without a previous history of thyrotoxicosis.  Clin Endocrinol (Oxf). 1994;  41 425-432
    PubMedSearch in Google Scholar
  • 20 Franklyn J A, Betteridge J, Holder R, Sheppard M C. Effect of estrogen replacement therapy upon bone mineral density in thyroxine-treated postmenopausal women with a history of thyrotoxicosis.  Thyroid. 1995;  5 359-363
    PubMedSearch in Google Scholar
  • 21 Frusciante V, Carnevale V, Scillitani A, Zingrillo M, Dicembrino F, Giannatempo G M, Ghiggi M R, Minisola S. Global skeletal uptake of technetium-99 m methylene diphosphonate in female patients receiving suppressive doses of L-thyroxine for differentiated thyroid cancer.  Eur J Nucl Med. 1998;  25 139-143
    CrossrefPubMedSearch in Google Scholar
  • 22 Fujiyama K, Kiriyama T, Ito M, Kimura H, Ashizawa Tsuruta K ;M, Nagayama Y, Villadolid M C, Yokoyama N, Nagataki S. Suppressive doses of thyroxine do not accelerate age-related bone loss in postmenopausal women.  Thyroid. 1995 a;  5 13-17
    PubMedSearch in Google Scholar
  • 23 Fujiyama K, Kiriyama T, Ito M, Nakata K, Yamashita H, Yokoyama N, Nagataki S. Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism.  J Clin Endocrinol Metab. 1995 b;  80 2135-2138
    CrossrefPubMedSearch in Google Scholar
  • 24 Gam A N, Jensen G F, Hasselstrom K, Olsen M, Nielsen K S. Effect of thyroxine therapy on bone metabolism in substituted hypothyroid patients with normal or suppressed levels of TSH.  J Endocrinol Invest. 1991;  14 451-455
    PubMedSearch in Google Scholar
  • 25 Garton M, Reid I, Loveridge N, Robins S, Murchinson L, Beckett G, Reid D. Bone mineral density and metabolism in premenopausal women taking L-thyroxine replacement therapy.  Clin Endocrinol (Oxf). 1994;  41 747-755
    PubMedSearch in Google Scholar
  • 26 Giannini S, Nobile M, Sartori L, Binotto Ciuffreda P ;M, Gemo G, Pelizzo Mr, D'Angelo A, Crepaldi G. Bone mineral density and metabolism in thyroidectomized patients treated with long-term L-thyroxine.  Clin Sci (Colch). 1994;  87 593-597
    PubMedSearch in Google Scholar
  • 27 Görres G, Kaim A, Otte A, Götze M, Müller-Brand J. Bone mineral density in patients receiving suppressive doses of thyroxine for differentiated carcinoma.  Eur J Nucl Med. 1996;  23 690-692
    PubMedSearch in Google Scholar
  • 28 Görres G, Theiler R, Müller-Brand J. Interfemur variation of bone density in patients receiving high-dose thyroxine therapy.  Calcif Tissue Int. 1998;  63 98-101
    CrossrefPubMedSearch in Google Scholar
  • 29 Gonzales D C, Mautalen C A, Correa P H, el Tamer E, el Tamer S. Bone mass in totally thyroidectomized patients. Role of calcitonin deficiency and exogenous thyroid treatment.  Acta Endocrinol (Copenh). 1991;  124 521-525
    PubMedSearch in Google Scholar
  • 30 Grant D J, McMurdo M E, Mole P A, Paterson C R, Davies R R. Suppressed TSH levels secondary to replacement therapy are not associated with osteoporosis.  Clin Endocrinol (Oxf). 1993;  39 529-533
    PubMedSearch in Google Scholar
  • 31 Greenspan S L, Greenspan F S, Resnick N M, Block J E, Friedlander A L, Genant H K. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy.  Am J Med. 1991;  91 5-14
    CrossrefPubMedSearch in Google Scholar
  • 32 Greenspan S L, Greenspan F S. The effect of thyroid hormone on skeletal integrity.  Ann Intern Med. 1999;  130 750-758
    PubMedSearch in Google Scholar
  • 33 Grimes D A, Schulz K F. An overview of clinical research: the lay of the land.  Lancet. 2002;  359 57-61
    CrossrefPubMedSearch in Google Scholar
  • 34 Guo C Y, Weetman A P, Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.  Clin Endocrinol. 1997;  46 301-307
    CrossrefPubMedSearch in Google Scholar
  • 35 Hadji P, Hars O, Sturm G, Bauer T, Emons G, Schulz K D. The effect of long-term, non-suppressive levothyroxine treatment on quantitative ultrasonometry of bone in women.  Eur J Endocrinol. 2000;  142 445-450
    CrossrefPubMedSearch in Google Scholar
  • 36 Hanna F W, Pettit R J, Ammari F, Evans W D, Sandeman D, Lazarus J H. Effect of replacement doses of thyroxine on bone mineral density.  Clin Endocrinol (Oxf). 1998;  48 229-234
    PubMedSearch in Google Scholar
  • 37 Hawkins F, Rigopoulou D, Papapietro K, Lopez M B. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.  Calcif Tissue Int. 1994;  54 16-19
    CrossrefPubMedSearch in Google Scholar
  • 38 Jodar E, Begona Lopez M, Garcia L, Rigoloulou D, Martinez G, Hawkins F. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.  Osteoporos Int. 1998;  8 311-316
    CrossrefPubMedSearch in Google Scholar
  • 39 Jodar E, Martinez-Diaz-Guerra G, Azriel S, Hawkins F. Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease.  Calcif Tissue Int. 2001;  69 84-87
    CrossrefPubMedSearch in Google Scholar
  • 40 Kann P, Jocham A, Beyer J. Hypothyreose, Hyperthyreose und Therapie mit Schilddrüsenhormonen: Einflüsse auf das Skelettsystem.  Dtsch med Wschr. 1997;  122 1392-1397
    PubMedSearch in Google Scholar
  • 41 Knudsen N, Faber J, Sierbaek-Nielsen A, Vadstrup S, Sörenson H A, Hegedüs L. Thyroid hormone replacement aiming at reduced, but not suppressed, serum thyroid-stimulating hormone levels in nontoxic goitre: effects on bone metabolism amongst premenopausal women.  J Intern Med. 1998;  243 149-154
    CrossrefPubMedSearch in Google Scholar
  • 42 Kung A WC, Pun K K. Bone mineral density in premenopausal women receiving long-term physiological doses of levothyroxine.  JAMA. 1991;  265 2688-2691
    CrossrefPubMedSearch in Google Scholar
  • 43 Kung A W, Lorentz T, Tam S C. Thyroxine suppressive therapy decreases bone mineral density in postmenopausal women.  Clin Endocrinol (Oxf). 1993;  39 535-540
    PubMedSearch in Google Scholar
  • 44 Kung A WC, Yeung S SC. Prevention of bone loss induced by thyroxine suppressive therapy in postmenopausal women: The effect of calcium and calcitonin.  J Clin Endocrinol Metab. 1996;  81 1232-1236
    CrossrefPubMedSearch in Google Scholar
  • 45 Lauwers A, Alexandre C. Impact of thyroid hormone therapy.  Rev Rhum. 1997;  64 112-119
    PubMedSearch in Google Scholar
  • 46 Langdahl B L, Loft A GR, Eriksen E F, Mosekilde L, Charles P. Bone mass, bone turnover and body composition in former hypothyroid patients receiving replacement therapy.  Eur J Endocrinol. 1996;  134 702-709
    CrossrefPubMedSearch in Google Scholar
  • 47 Lecomte P, Lecureuil N, Osorio-Salazar C, Lecureuil M, Valat C. Effects of suppressive doses of levothyroxine treatment on sex-binding globulin and bone metabolism.  Thyroid. 1995;  5 19-23
    PubMedSearch in Google Scholar
  • 48 Lehmke J, Bogner U, Felsenberg D, Peters H, Schleusener H. Determination of bone mineral density by quantitative computed tomography and single photon absorptiometry in subclinical hyperthyroidism: a risk of early osteopenia in postmenopausal women.  Clin Endocrinol (Oxf). 1992;  36 511-551
    PubMedSearch in Google Scholar
  • 49 Marcocci C, Golia F, Bruno-Bossio G, Vignali E. Carefully monitored levothyroxine therapy is not associated with bone loss in premenopausal women.  J Clin Endocrinol Metab. 1994;  78 818-823
    CrossrefPubMedSearch in Google Scholar
  • 50 Marcocci C, Golia F, Vignali E, Pinchero A. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.  J Bone Miner Res. 1997;  12 72-77
    PubMedSearch in Google Scholar
  • 51 McDermott M T, Perloff J J, Kidd G S. A longitudinal assessment of bone loss in women with levothyroxine-suppressive benign thyroid disease and thyroid cancer.  Calcif Tissue Int. 1995;  56 521-525
    CrossrefPubMedSearch in Google Scholar
  • 52 Mirzaei S, Krotla G, Knoll P, Korsika K, Köhn H. Possible effect of calcitonin deficiency on bone mass after subtotal thyroidectomy.  Acta Med Austriatica. 1999;  26 29-31
    PubMedSearch in Google Scholar
  • 53 Müller C G, Bayley T A, Harrison J E, Tsang R. Possible limited bone loss with suppressive thyroxine therapy is unlikely to have clinical relevance.  Thyroid. 1995;  5 81-87
    PubMedSearch in Google Scholar
  • 54 Nuzzo V, Lupoldi G, Esposito Del Puente A, Rampone E, Carpinelli A, Del Puente A E, Oriente P. Bone mineral density in premenopausal women receiving levothyroxine suppressive therapy.  Gynecol Endocrinol. 1998;  12 333-337
    PubMedSearch in Google Scholar
  • 55 Ongphiphadhanakul B, Puavilai G, Rajatanavin R. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.  J Med Assoc Thai. 1996;  79 563-567
    PubMedSearch in Google Scholar
  • 56 Oxman A D. Checklist for review articles.  BMJ. 1994;  309 648-651
    CrossrefPubMedSearch in Google Scholar
  • 57 Pines A, Dotan I, Tabori U, Villa Y, Mijatovic V, Levo Y, Ayalon D. L-thyroxine prevents the bone-conserving effect of HRT in postmenopausal women with subclinical hypothyroidism.  Gynecol Endocrinol. 1999;  13 196-201
    PubMedSearch in Google Scholar
  • 58 Pioli G, Pedrazzoni M, Palummeri E, Sianesi M, Del Frate R, Vescovi P P, Prisco M, Ulietti V, Costi D, Passeri M. Longitudinal study of bone loss after thyroidectomy and suppressive thyroxine therapy in premenopausal women.  Acta Endocrinol (Copenh). 1992;  126 238-242
    PubMedSearch in Google Scholar
  • 59 Quan M L, Pasieka J L, Rorstad O. Bone mineral density in well-differentiated thyroid cancer patients treated with suppressive thyroxine: a systematic overview of the literature.  J Surg Oncol. 2002;  79 62-70
    CrossrefPubMedSearch in Google Scholar
  • 60 Radetti G, Castellan C, Tato L, Platter K, Gentili L, Adami S. Bone mineral density in children and adolescent females treated with high doses of L-thyroxine.  Horm Res. 1993;  39 127-131
    PubMedSearch in Google Scholar
  • 61 Ribot C, Tremollieres F, Pouilles J M, Louvet J P. Bone mineral density and thyroid hormone therapy.  Clin Endocrinol (Oxf). 1990;  33 143-153
    PubMedSearch in Google Scholar
  • 62 Rosen H N, Moses A C, Garber J, Ross D S, Lee S L, Ferguson L, Chen V, Lee K, Greenspan S L. Randomized trial of pamidronate in patients with thyroid cancer: Bone density is not reduced by suppressive doses of thyroxine, but is increased by cyclic intravenous pamidronate.  J Clin Endocrinol Metab. 1998;  83 2324-2330
    CrossrefPubMedSearch in Google Scholar
  • 63 Ross D S. Bone density is not reduced during the short-term administration of levothyroxine to postmenopausal women with hypothyroidism: a randomized, prospective study.  Am J Med. 1993;  95 385-388
    CrossrefPubMedSearch in Google Scholar
  • 64 Ross D S. Hyperthyroidism, thyroid hormone therapy, and bone.  Thyroid. 1994;  4 319-326
    PubMedSearch in Google Scholar
  • 65 Saggese G, Bertelloni S, Baroncelli G I, Costa S, Ceccarelli C. Bone mineral density in adolescent females treated with L-thyroxine: a longitudinal study.  Eur J Pediatr. 1996;  155 452-457
    PubMedSearch in Google Scholar
  • 66 Schneider P, Berger P, Kruse K, Börner W. Effect of calcitonin deficiency on bone density and bone turnover in totally thyroidectomized patients.  J Endocrinol Invest. 1991;  14 934-942
    PubMedSearch in Google Scholar
  • 67 Schneider D L, Barrett-Connor E L, Morton D J. Thyroid hormone use and bone mineral density in elderly women.  JAMA. 1994;  271 1245-1249
    CrossrefPubMedSearch in Google Scholar
  • 68 Schneider D L, Barrett-Connor E L, Morton D J. Thyroid hormone use and bone mineral density in elderly men.  Arch Intern Med. 1995;  155 2005-2007
    CrossrefPubMedSearch in Google Scholar
  • 69 Singh N, Singh P N, Hershman J M. Effect of calcium carbonate on the absorption of levothyroxine.  JAMA. 2000;  283 2822-2825
    CrossrefPubMedSearch in Google Scholar
  • 70 Siris E S, Miller P D, Barrett-Connor E, Faulkner K G, Wehren L E, Abbott T A, Berger M L, Santora A C, Sherwood L M. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women.  JAMA. 2001;  22 2815-2822
    PubMedSearch in Google Scholar
  • 71 Stall G M, Harris S, Sokoll L J, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine.  Ann Intern Med. 1990;  113 265-269
    PubMedSearch in Google Scholar
  • 72 Stefan J J, Limanova Z. Biochemical assessment of bone loss in patients on long-term thyroid hormone treatment.  Bone Miner. 1992;  17 377-388
    CrossrefPubMedSearch in Google Scholar
  • 73 Taelman P, Kaufman J M, Janssens X, Vandecauter H, Vermeulen A. Reduced forearm bone mineral content and biochemical evidence of increased bone turnover in women with euthyroid goitre treated with thyroid hormone.  Clin Endocrinol (Oxf). 1990;  33 107-117
    PubMedSearch in Google Scholar
  • 74 Toh S H, Brown P H. Bone mineral content in hypothyroid male patients with hormone replacement: A 3-year study.  J Bone Miner Res. 1990;  5 463-467
    PubMedSearch in Google Scholar
  • 75 Toivonen J, Tahtela R, Laitinen K, Ristele J, Valimaki M J. Markers of bone turnover in patients with differentiated thyroid cancer and following withdrawal of thyroxine therapy.  Eur J Endocrinol. 1998;  138 667-673
    CrossrefPubMedSearch in Google Scholar
  • 76 Tümer L, Hasanoglu A, Cinaz P, Aysun B. Bone mineral density and metabolism in children treated with L-thyroxine.  J Pediatr Endocrinol Metab. 1999;  12 519-523
    PubMedSearch in Google Scholar
  • 77 Uzzan B, Campos J, Cucherat M, Nony P, Boissel J P, Perret G Y. Effects on bone mass of long-term treatment with thyroid hormones: A meta-analysis.  J Clin Endocrinol Metab. 1996;  81 4278-4289
    CrossrefPubMedSearch in Google Scholar
  • 78 Williams J B. Adverse effects of thyroid hormones.  Drugs Aging. 1997;  11 460-469
    PubMedSearch in Google Scholar
  • 79 Wüster C, Raue F, Meyer C, Bergmann M, Ziegler R. Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density.  J Endocrinol. 1992;  134 141-147
    PubMedSearch in Google Scholar

Dr. Rita Schneider

Clinic for Nuclear Medicine

Josef-Schneider-Straße 2

97080 Würzburg

Germany

Phone: + 4993120135096

Fax: + 49 9 31 20 13 52 47

Email: schneider_r1@nuklearmedizin.uni-wuerzburg.de